Zebra Medical Vision’s AI solutions to be available through Nuance marketplace

Zebra Medical Vision has announced that its bundle of AI-focused solutions will be available through the Nuance AI Marketplace. The app store-like marketplace gives users of Nuance’s PowerScribe reporting system access to products from a number of different vendors.

“We are thrilled that our software will now be available on the Nuance AI Marketplace,” John LoGioco, CCO of Zebra Medical Vision, said in a prepared statement. “This collaboration will give us maximum exposure on one of the largest and most reputable portals, with one-stop access to a wide range of AI diagnostic models. Our work with Nuance will enable Zebra-Med’s products to impact the health of many more patients, through the industry’s most widely used radiology reporting platform.”

Zebra Medical Vision’s AI1 bundle includes a triage solution for head CT scans, a breast cancer package for mammograms and two additional solutions focused on population health—one for bone health and another for heart health. The official launch of the AI1 bundle is scheduled for RSNA 2019 in Chicago.   

In October, Densitas and MaxQAI both announced they would have solutions available through the Nuance AI Marketplace. More information on the marketplace is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.